Journal of Cardiovascular Pharmacology
Overview
The Journal of Cardiovascular Pharmacology is a peer-reviewed scientific journal that focuses on the study of pharmacological interventions and therapies for cardiovascular diseases. It publishes original research articles, reviews, and clinical trials, covering topics such as drug development, mechanisms of action, drug interactions, and therapeutic outcomes. The journal serves as a valuable resource for researchers, clinicians, and pharmacologists interested in advancing the field of cardiovascular pharmacology.
Details
Details
Abbr.
J Cardiovasc Pharmacol
Start
1979
End
Continuing
Frequency
Monthly
p-ISSN
0160-2446
e-ISSN
1533-4023
Country
United States
Language
English
Metrics
Metrics
h-index / Ranks: 2665
109
SJR / Ranks: 7374
610
CiteScore / Ranks: 6010
4.40
JIF / Ranks: 3481
3.0
Recent Articles
1.
Del Buono M, Filomia S, DAiello A, Sanna T
J Cardiovasc Pharmacol
. 2025 Mar;
PMID: 40053571
No abstract available.
2.
Biondi-Zoccai G, Galli M, Booz G
J Cardiovasc Pharmacol
. 2025 Mar;
85(3):238.
PMID: 40047794
No abstract available.
3.
Coupling Interval Ratio to Predict the Beta Blocker Response against Premature Ventricular Complexes
Atmaca H, Yetkin E
J Cardiovasc Pharmacol
. 2025 Feb;
PMID: 40020078
Despite the wide-spread use of beta blockers, unpredictable response and overall low efficacy are the major pitfalls of beta blocker use for premature ventricular complexes (PVC). Accordingly, we aimed to...
4.
5.
Krieger-Burke T, Yoder E, Frisbee J, Garver H, Fink G, Watts S
J Cardiovasc Pharmacol
. 2025 Feb;
PMID: 40019945
Serotonin (5-hydroxytryptamine, 5-HT) at low plasma concentrations reduces blood pressure and dilates some skeletal muscle arterioles in the rat. We hypothesized that the 5-HT7 receptor is essential for both 5-HT-induced...
6.
Biondi-Zoccai G, Weber B, Abbate A, Booz G
J Cardiovasc Pharmacol
. 2025 Feb;
PMID: 40014789
Immuno-cardiology is an emerging field that explores the interplay between the immune system, inflammation and cardiovascular health/disease, aiming to develop innovative therapies for preventing and treating cardiac diseases. Indeed, chronic...
7.
Li C, Wu R, Xie Q, Wang F, Le Xu X
J Cardiovasc Pharmacol
. 2025 Feb;
PMID: 39970127
Procyanidin B2 (PB2) is a prominent procyanidin isomer. Its effects and mechanisms in cardiac remodeling are not fully understood. Peroxisome proliferator-activated receptor gamma (PPAR-γ) plays a crucial role in regulating...
8.
Gragnano F, Calabro P, Angiolillo D
J Cardiovasc Pharmacol
. 2025 Feb;
PMID: 39960868
No abstract available.
9.
Jansen S, Jansen S, Pitek R, Karsdal M, Henriksen K
J Cardiovasc Pharmacol
. 2025 Feb;
PMID: 39933048
The NC1 domains of collagens have been shown to possess antiangiogenic potential and, therefore, are of therapeutic interest for cancer. However, endostatin and other NC1 domains have not been successful...
10.
Pepe M, Tritto R, Napoli G, Giordano S, Romito R, Biondi-Zoccai G, et al.
J Cardiovasc Pharmacol
. 2025 Feb;
PMID: 39933047
The management of antiplatelet therapy in coronary artery disease (CAD) is one of the most debated topics in cardiology. In some clinical scenarios, such as acute coronary syndromes (ACS) and/or...